Porton Pharma Solutions Ltd.

300363

CNE100001S57

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
15.49 ^CNY	-2.82%		-5.09%	-38.41%

26/04	Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/04	Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Porton Pharma Solutions Ltd. Announces Board Changes

September 30, 2020 at 01:03 am IST

Porton Pharma Solutions Ltd. approved By-election of TAO EN as a non-independent director, Xue Ying as a non-independent director and Cao Guohua as independent director.

Latest news about Porton Pharma Solutions Ltd.

Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/04	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023.	09/04	CI
Porton Pharma Solutions Ltd.'s Equity Buyback announced on October 28, 2023, has closed with 1,260,000 shares, representing 0.23% for CNY 29.87 million.	09/04	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023.	03/04	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on October 28, 2023.	03/01	CI
Porton Pharma Solutions Ltd. announces an Equity Buyback for CNY 30 million worth of its shares.	27/23/27	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Porton Pharma Solutions Ltd. authorizes a Buyback Plan.	27/23/27	CI
Porton Pharma Solutions Ltd. agreed to acquire 30% stake in Hubei Yuyang Pharmaceutical Co., Ltd. for CNY73.5 million.	15/23/15	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	18/23/18	CI
Porton Pharma Solutions Ltd. Announces Final Dividend for the Year 2022, Payable on 09 May 2023	29/23/29	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	21/23/21	CI
Porton Pharma Solutions Ltd. Approves Cash Dividend for the Year 2022	19/23/19	CI
Porton Pharma Sees Up to 25% Profit Drop in Q1 on Lower Orders	03/23/03	MT
Porton Pharma Solutions Ltd. Proposes Profit Distribution for 2022	27/23/27	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Porton Pharma to Build 2.5 Billion Yuan Drug R&D, Production Facility	20/23/20	MT
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on August 4, 2022.	22/22/22	CI
Porton Pharma Solutions Ltd.'s Equity Buyback announced on August 4, 2022, has closed with 2,022,344 shares, representing 0.37% for CNY 100 million.	21/22/21	CI
Shanghai Feiteng Pharmaceutical Technology Co., Ltd. announced that it has received CNY 60 million in funding from Porton Pharma Solutions Ltd.	27/22/27	CI
Porton Pharma Solutions Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Tranche Update on Porton Pharma Solutions Ltd.'s Equity Buyback Plan announced on August 4, 2022.	10/22/10	CI
Porton Pharma Solutions Ltd.(XSEC:300363) added to S&P Global BMI Index	19/22/19	CI
Porton Pharma Solutions Ltd.(XSEC:300363) added to FTSE All-World Index	19/22/19	CI

Chart Porton Pharma Solutions Ltd.

Duration

Period

More charts

Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The Company operates its businesses in Europe, North America, Asia and China, among others.

Sector

Pharmaceuticals

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Porton Pharma Solutions Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.49 CNY

Average target price

26.65 CNY

Spread / Average Target

+72.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PORTON PHARMA SOLUTIONS LTD.	-38.41%	1.2B
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals